Thomasville National Bank lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,396 shares of the company’s stock after purchasing an additional 435 shares during the period. Thomasville National Bank’s holdings in Johnson & Johnson were worth $3,467,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. Innealta Capital LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $27,000. MFA Wealth Advisors LLC acquired a new position in Johnson & Johnson during the second quarter valued at $43,000. Fairfield Financial Advisors LTD acquired a new position in Johnson & Johnson during the second quarter valued at $46,000. Grayhawk Investment Strategies Inc. raised its position in Johnson & Johnson by 528.6% during the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after buying an additional 259 shares during the period. Finally, Fairway Wealth LLC raised its position in Johnson & Johnson by 217.1% during the second quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock valued at $49,000 after buying an additional 228 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Johnson & Johnson
In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on JNJ
Johnson & Johnson Stock Performance
JNJ opened at $161.46 on Monday. The company has a market cap of $388.58 billion, a PE ratio of 10.07, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52. The stock has a 50-day moving average of $162.59 and a 200-day moving average of $154.46. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter in the prior year, the company posted $2.80 EPS. The firm’s revenue was up 4.3% on a year-over-year basis. As a group, equities research analysts forecast that Johnson & Johnson will post 10 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were paid a dividend of $1.24 per share. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.07%. Johnson & Johnson’s payout ratio is 30.92%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- What Are Some of the Best Large-Cap Stocks to Buy?
- BlackRock’s Earnings Reveal Market Shift: Why Bonds Are in Favor
- 3 REITs to Buy and Hold for the Long Term
- JPMorgan Can Hit New Highs This Year: Here’s Why
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Best Pharma Stocks for Long-Term Investors: Growth and Dividends
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.